声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。作为业内公认的“中国BD之王”，和铂医药通过持续的商业拓展（BD）合作及其底层技术平台价值的释放，实现了显著的业绩增长。8月27日，和铂医药公布了2025年中期业绩及公司业务进展。财报显示，和铂医药上半年总收入约7.25亿元人民币（约1.01亿美元），...
Source Link声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。作为业内公认的“中国BD之王”，和铂医药通过持续的商业拓展（BD）合作及其底层技术平台价值的释放，实现了显著的业绩增长。8月27日，和铂医药公布了2025年中期业绩及公司业务进展。财报显示，和铂医药上半年总收入约7.25亿元人民币（约1.01亿美元），...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.